UCB Current and Future Leadership
Perspectives in Epilepsy Treatment
and Care
9th January 2023
Proprietary and Confidential Property of UCB
Disclaimer and Safe Harbor
This presentation contains forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.
Important factors that could result in such differences include but are not limited to: global spread and impacts of wars and pandemics, including COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.
Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this presentation, and do not reflect any potential impacts from the evolving war in Ukraine and COVID-19 pandemic, unless indicated otherwise. The company continues to follow the development diligently to assess the financial significance of this pandemic to UCB.
UCB expressly disclaims any obligation to update any forward-looking statements in this presentation, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.
Proprietary and Confidential Property of UCB
Proprietary and Confidential Property of UCB | 2 |
Our Global Epilepsy
Charl van Zyl Executive Vice President, International Markets/Europe,
Antje Witte | |
Head of Investor Relations, UCB | |
Charl van Zyl | |
Executive Vice President, UCB | |
Neurology Solutions | |
& Head of EU and International Markets | |
Mike Davis | |
Head of Global Epilepsy, UCB | |
Agenda | Konrad Werhahn, MD PhD |
Head of Medical Affairs, Epileptologist, UCB | |
Stefanie Dedeurwaerdere, PhD | |
Head of Epilepsy Discovery, UCB | |
Charl van Zyl | |
Executive Vice President, UCB | |
Neurology Solutions | |
& Head of EU and International Markets | |
All Speakers |
Welcome
Our Epilepsy Leadership
Our Unified Epilepsy Strategy
Fintepla®▼ (fenfluramine oral solution) Provides a New Set of
Answers in Dravet & Lennox Gastaut Syndrome
Early Solutions: Leveraging Novel Science and Human Pathobiology for Improved Drug Targeting in Epilepsy
Summary: Evolution of UCB's Epilepsy Pipeline into Precision Medicine with the Continued Ambition for Curative Therapy
Q&A Session
Proprietary and Confidential Property of UCB
Disclaimer: FINTEPLA is not approved in all geographies where we operate
4
Across UCB we are defined by our purpose:
Creating value for patients now and into the future
and sustainability is our business approach.
We believe that everyone deserves to live the best life that they can - as free as possible from the challenges and uncertainty of disease
Proprietary and Confidential Property of UCB
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
UCB SA published this content on 09 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 January 2023 09:28:06 UTC.